Ustekinumab in Psoriasis Immunopathology with Emphasis on the Th17-IL23 Axis: A Primer by Quatresooz, Pascale et al.
Hindawi Publishing Corporation
Journal of Biomedicine and Biotechnology
Volume 2012, Article ID 147413, 5 pages
doi:10.1155/2012/147413
Review Article
UstekinumabinPsoriasis ImmunopathologywithEmphasison
the Th17-IL23 Axis: A Primer
Pascale Quatresooz,1 TrinhHermanns-Lˆ e,1 G´ eraldE.Pi´ erard,1,2 Philippe Humbert,2,3,4
Philippe Delvenne,1 andClaudinePi´ erard-Franchimont1
1Department of Dermatopathology, University Hospital of Li` ege, 4000 Li` ege, Belgium
2Faculty of Medicine, University of Franche-Comt´ e, 25000 Besanc ¸on, France
3Department of Dermatology, University Hospital of Besanc ¸on, 25000 Besanc ¸on, France
4Inserm Research Unit U645, IFR133, 25000 Besanc ¸on, France
Correspondence should be addressed to G´ erald E. Pi´ erard, gerald.pierard@ulg.ac.be
Received 31 January 2012; Revised 5 March 2012; Accepted 5 March 2012
Academic Editor: Enzo Berardesca
Copyright © 2012 Pascale Quatresooz et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Psoriasis is a chronic relapsing immunoinﬂammatory dermatosis that is commonly associated with systemic comorbidities. The
pathogenic importance of interleukin (IL)-12 and IL-23 is beyond doubt, as well as the involvement of T helper cells (Th)1 and
Th17 cells. There is upregulation of the p40 subunit shared by IL-12 and IL-23 and of the IL-23 p19 subunit, but not an increased
expression of the IL-12 p35 subunit. This indicates that IL-23 appears more involved than IL-12 in the pathogenesis of psoriatic
plaques. Ustekinumab is a fully human monoclonal antibody of the immunoglobulin (Ig) G1 class targeting the p40 subunit
common to both IL-12 and IL-23, thus inhibiting both IL-12 and IL-23 receptor-mediated signalling. Ustekinumab is part of the
recent biologic therapies active in psoriasis, autoimmune arthritides, and inﬂammatory bowel diseases.
1. Introduction
Disturbed immune-mediated inﬂammatory reactions are
involved in the pathogenesis of psoriasis and its comor-
bidities [1]. There is evidence that the combined epidermal
and microvasculature hyperplasia results from a response
to the immune cell inﬁltrate present in the skin [2–4]. In
recent years, some speciﬁc inﬂammatory cytokine pathways
haverepresentedpromisingorestablishedtherapeutictargets
[1–6]. In particular, biologicals directed to tumor necrosis
factor(TNF)-α,interleukin(IL)-12,IL-23,aswellasCD4+T
helper (Th) 1 and Th17 eﬀector cells ﬁtted with the psoriasis
pathobiology [7, 8].
2. The IL-12 / IL-23 Connection
IL-12 and IL-23 are structurally related cytokines that upreg-
ulate T-cell immune responses [9]. IL-12 is a heterodimeric
protein consisting of the two disulﬁde-linked, glycosylated
p35 and p40 subunits. This cytokine is secreted by dendritic
antigen-presenting cells in response to inﬂammatory stimuli
or infections. The IL-12 cytokine activates natural killer
(NK) and T-cell responses, including naive CD4+ T-cell
diﬀerentiation toward the CD4+ Th1 phenotype [9–11].
The heterodimeric IL23 cytokine contains the identical p40
subunit disulﬁde-linked to a p19 subunit [11]. Following
activation by IL-6 and transforming growth factor (TGF)-
β, IL-23 in concert with TNFα supports the development of
Th17 cells [9–13].
The p40 subunit of both IL-12 and IL-23 binds to the IL-
12receptor-β1(IL-12Rβ1)[14,15].TheIL-12p35andtheIL-
23p19 subunits bind to IL-12Rβ2 and IL-23R, respectively.
These distinct binding processes account for the cytokine
biological speciﬁcities [11, 14, 15]. Thus, despite some
structural similarities between IL-12 and IL-23, they control
distinct immunological pathways. IL-12 promotes the devel-
opment of Th1 populations producing interferon (IFN)-γ,
TNF-α, and IL-2. By contrast, IL-23 in combination with
IL-21 and TGFβ drives the development of CD4+ Th17
populations producing IL-17, IL-22, TNF-α,a n dI L - 1 β [16].2 Journal of Biomedicine and Biotechnology
3. PsoriasisImmunopathogenesis
Psoriasis apparently results from the activation of an abnor-
mal immune response leading to excessive keratinocyte
proliferation and global epidermal thickening. In particular,
cytokines produced by Th1 and Th17 cell populations play a
pivotal role in the development and maintenance of psoriatic
lesions [13–15, 17–19]. The p40-containing cytokines are
involved in the psoriasis pathogenesis [17] because there
is overexpression of the IL-12p40 and the IL-23p40 in
psoriasis plaques [20–22]. Gene polymorphisms encoding
the shared p40 subunit or one of the components of the IL-
23 receptor (IL-23R) complex are linked to psoriasis [23].
An uncommon IL-23R coding variant protecting against
Crohn’sdiseaseappearstoconferprotectionagainstpsoriasis
[24, 25]. Gene expression levels of IL-12p40, IFN-γ,a n dI L -
23p49 are raised in psoriatic lesions [21, 23, 26]. Both IL-17
and IL-22 promote epidermal proliferation and remodelling,
through activation of the keratinocyte transcription factor
Stat3, and upregulate keratinocyte host defence proteins,
including human β-defensin (HβD)-2 [19, 27]. IFN-γ in
c o n c e r tw i t hS t a t1a c t i v a t e sk e r a t i n o c y t e st ou p r e g u l a t e
major histocompatibility complex class II, while both intra-
cellular adhesion molecules (ICAM) and TNFα contribute
to the development of psoriatic plaques [1, 18, 28, 29]. In
addition, IL-23 drives monocytes to diﬀerentiate into den-
dritic cells [30]. This might account for the presence of many
factor XIIIa+ dermal dendrocytes.
Th1 and Th17 cells are involved in the psoriasis patho-
biology following secretion of a series of inﬂammatory
cytokines, including IFN-γ, IL-17, and IL-22, that in turn
activate keratinocytes to proliferate and secrete additional
proinﬂammatory mediators [5]. The IL-12 and IL-23
cytokines produce a downstream impact on Th1 and Th17
cellactivation,aswellaskeratinocytetriggering.Accordingly,
any therapeutic agent designed to block IL-12 and IL-23
likely abates the upregulation of IFN-γ, IL-17, and IL-22 by
both Th1 and Th17 cells [5].
Th17 cells play a central role in the development of pso-
riasis [2, 31]. IL-23 represents the major regulator of Th17
cells. These cells conduct immunosurveillance in the epider-
mis and secrete IL-17A, IL-17F, and IL-22 [32]. In psoriatic
lesions, the proinﬂammatory IL-17 leads to the production
of other cytokines and angiogenic factors, committing naive
T cells to the Th17 lineage and creating a positive feedback
loop for Th17 inﬂammation. IL-22 acts on keratinocytes
through the IL-22 and IL-10 receptors, resulting in hyper-
proliferation and altered keratinocyte maturation leading to
the typical acanthosis of psoriatic lesions [33, 34]. IL-17 and
IL-22 produce a synergist stimulation of keratinocytes to be
resistant to microbial infection through the expression of
antimicrobial peptides. Some Th17 cells produce IL-17 only,
while Th22 cells solely produce IL-22 [35, 36].
Both IL-12 and IL-23 are overexpressed in lesional psori-
atic skin. However, the p40 subunit was used as a surrogate
for assessing IL-12 expression. Thus, no diﬀerentiation was
possible between the presence of IL-12 and IL-23 [37–40]. A
pivotal study showed RNA upregulation of the p40 subunit
shared by IL-12 and IL-23 and of the IL-23p19 subunit, but
not an increased expression of the IL-12p35 subunit [38].
Such ﬁnding suggested that IL-23 was more involved in the
maintenanceofpsoriaticlesionsthanIL-12.Additionally,IL-
23 is a more potent activator of keratinocyte proliferation
than IL-12 [39, 40].
4. Ustekinumab
The psoriasis immunopathogenesis has provided new ther-
apeutic options in recent years [7]. Among recent break-
throughs, ustekinumab (Stelara, Janssen Pharmaceutica,
Beerse, Belgium) is a fully human monoclonal antibody of
the IgG1 class. It is directed to the shared p40 subunit of
both IL-12 and IL-23 [41–43]. Thus, the drug neutralizes the
bioactivities of both cytokines by blocking interaction with
the IL-12R β1 cell surface receptor. The pharmacological
characteristics and both the clinical eﬃcacy and tolerability
of ustekinumab are clearly proven in patients with chronic
moderate to severe plaque psoriasis, including subjects with
psoriatic onychopathy and psoriatic arthritis [8, 43–46].
IL-23 expression is signiﬁcantly increased in the psoriatic
epidermis [5, 38]. IL-23 messenger RNA expression is
signiﬁcantly higher in lesional skin of psoriatic patients as
compared with healthy skin in the same patients [5, 38]. IL-
23secretionbymonocytesandmaturedendriticcellsderived
from patients with psoriasis is unusually high [38]. This
cytokine promotes survival and proliferation of Th17 cells
[47–51]. As a result, Th17 cytokines, such as IL-17, stimulate
keratinocyte proliferation enabling further stimulation of
keratinocyte proliferation in psoriatic lesions [6, 29].
The therapeutic eﬃcacy of ustekinumab is obtained after
IL-12 and IL-23 inhibition leading to the abated expression
of cell surface markers associated with skin homing (CLA),
activation of anti-inﬂammatory cytokines including IL-5,
and inhibition of the secretion of the proinﬂammatory
cytokines IFNγ, IL-2, IL-8, IL-10, IL-17A, and TNFα.A
reduction in CD4+ Th cells and NK cells was reported
after a single dose of ustekinumab. However, changes varied
a c r o s st i m ea n dd i dn o ta p p e a rt ob ed o s ed e p e n d e n t .
Ustekinumab pharmacokinetics is notably aﬀected by body
weight. This aspect is particularly important to consider in
case of metabolic syndrome comorbidity.
5. Beyond Psoriasis
Recent clinical trials conducted in humans emphasized the
crucial role of Th17 cells boosted by IL-23 in the immuno-
pathogenesis of several other inﬂammatory skin diseases,
including allergic contact dermatitis, systemic scleroderma,
and sarcoidosis [52–58]. In addition, the IL-23/Th17 axis
appears to play a prominent role in the development of
other diseases with possible cutaneous involvement. These
include systemic lupus erythematosus [59, 60], rheumatoid
arthritis [61], inﬂammatory bowel disease [62], and Behc ¸et
disease [63]. Considering the major role of IL-23-dependent
Th17 cells in several skin diseases, future indications for IL-
23 pathway inhibitors will probably emerge in a ﬁeld much
more broader than currently documented.Journal of Biomedicine and Biotechnology 3
At present, the advent of biological therapies has
alreadyrevolutionizedthetreatmentofautoimmunediseases
beyond psoriasis, including autoimmune arthritides, and
inﬂammatory bowel diseases.
6. Conclusion
Psoriasis is a frequent chronic relapsing immunoinﬂamma-
tory dermatitis particularly triggered by the Th17/IL-23 axis.
The long-term limitations of conventional systemic psoriasis
therapies because of the potential for severe renal, hepatic,
and pulmonary adverse events have led to the develop-
ment of biotherapies. An increased understanding of the
immunopathogenesisofpsoriasishelpedfocusingonspeciﬁc
targets. These agents alter speciﬁc immunologic pathways
involved in the development of the disease, including some
cytokine productions. At present, it appears that IL-23 is
more involved than IL-12 in the pathogenesis of psoriasis.
Ustekinumab is a monoclonal antibody to the common
p40 subunit shared by IL-12 and IL-23. It represents a mas-
terpiece in the treatment of plaque psoriasis. Other condi-
tions including psoriatic arthritis, Crohn’s disease, and some
other autoimmune diseases are expected to become recog-
nized indications for the drug.
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